secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001140361-25-016562
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q1 revenue up 10% to $132M; TRYNGOLZA brings $6M, guidance raised >20%
----------------------------------------------------------------------------

- Revenue $132M (+10% YoY); TRYNGOLZA product sales $6M; royalty revenue $64M (SPINRAZA $48M, WAINUA $9M).
- GAAP operating loss $146M (non-GAAP $117M); FY2025 revenue guidance raised to $725-750M from >$600M.
- Donidalorsen PDUFA Aug 21, 2025; olezarsen Phase 3 sHTG data Q3 2025; ION582 Phase 3 Angelman Q2 2025.
- Sapablursen licensed to Ono for $280M upfront; potential $660M milestones plus mid-teen royalties.
- Cash & investments $2.1B at Mar 31; expected ~$1.9B year-end after $280M Q2 inflow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125016562/0001140361-25-016562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125016562/ef20048172_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-016562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer